Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bio Green Med Solution, Inc.CYCC · Entity 8225 | Director | June 30, 2023 | July 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bio Green Med Solution, Inc.
Report date June 30, 2023 · Filed July 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,952 |
Reported balance
After 2023-06-30 transaction · row 1
1 source rowRow 1 · 2023-06-30 · Grant · Acquired 21,219 · Balance 44,952 F1: The reporting person received an award of 21,219 restricted stock units on June 30, 2023, which shall vest in full on June 30, 2024. F2: These securities were granted to Dr. Ferguson for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.59 · Expires 2033-06-30 | Direct | 42,438 |
Reported balance
After 2023-06-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-30 · Grant · Acquired 42,438 · Balance 42,438 F2: These securities were granted to Dr. Ferguson for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person received an award of 21,219 restricted stock units on June 30, 2023, which shall vest in full on June 30, 2024.
F2: These securities were granted to Dr. Ferguson for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2023 Filed Jul 3, 2023 20:56 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantStock Option (right to buy) · Derivative | 42,438 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001104659-23-077652 · tm2320411-3_4seq1.xml · derivative · entry 2 Ferguson Kenneth M. · CIK 0001934344 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,438 Underlying: Common Stock · 42,438 shares Expires 2033-06-30 F2 · price: These securities were granted to Dr. Ferguson for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 20:56 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantCommon Stock | 21,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-077652 · tm2320411-3_4seq1.xml · nonDerivative · entry 1 Ferguson Kenneth M. · CIK 0001934344 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,952 F1 · shares: The reporting person received an award of 21,219 restricted stock units on June 30, 2023, which shall vest in full on June 30, 2024. F2 · price: These securities were granted to Dr. Ferguson for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:39 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantStock Option (right to buy) · Derivative | 47,467 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001104659-22-071945 · tm2218645d8_4.xml · derivative · entry 2 Ferguson Kenneth M. · CIK 0001934344 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,467 Underlying: Common Stock · 47,467 shares Expires 2032-06-14 F2 · price: The option will vest and become exercisable in equal monthly installments for thirty-six months beginning on the date of the grant, which is June 14, 2022, subject to the Reporting Person continuing to provide services to the Issuer through each such vesting date. F3 · price: These options were granted to Mr. Ferguson for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:39 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantCommon Stock | 27,733 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-071945 · tm2218645d8_4.xml · nonDerivative · entry 1 Ferguson Kenneth M. · CIK 0001934344 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,733 F1 · shares: The Reporting Person received an award of 27,733 restricted stock units on June 14, 2022, which shall vest in three equal installments on June 14, 2023, June 14, 2024, and June 14, 2025. Read SEC document |
| June 14, 2022 Filed Jun 17, 2022 20:06 UTC Amendment | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantStock Option (right to buy) · Derivative | 47,467 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001104659-22-072381 · tm2218810-1_4a.xml · derivative · entry 2 Ferguson Kenneth M. · CIK 0001934344 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,467 Underlying: Common Stock · 47,467 shares Expires 2032-06-14 F3 · price: The option will vest and become exercisable in equal monthly installments for thirty-six months beginning on the date of the grant, which is June 14, 2022, subject to the Reporting Person continuing to provide services to the Issuer through each such vesting date. F4 · price: These options were granted to Mr. Ferguson for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 14, 2022 Filed Jun 17, 2022 20:06 UTC Amendment | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantCommon Stock | 23,733 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-072381 · tm2218810-1_4a.xml · nonDerivative · entry 1 Ferguson Kenneth M. · CIK 0001934344 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,733 F1 · shares: The Reporting Person received an award of 23,733 restricted stock units on June 14, 2022, which shall vest in three equal installments on June 14, 2023, June 14, 2024, and June 14, 2025. F2 · shares: This Form 4 is being amended to correct a typographical error in the number of restricted stock units granted to the Reporting Person on June 14, 2022. 23,733 shares of restricted stock units were granted to the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.